Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report

[1]  B. Dréno,et al.  Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline , 2016, Experimental dermatology.

[2]  Suzanne E Dahlberg,et al.  Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. , 2016, JAMA oncology.

[3]  B. Neyns,et al.  Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors , 2016, Journal of Translational Medicine.

[4]  A. Hauschild,et al.  Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials , 2015, Clinical Cancer Research.

[5]  A. Marchetti,et al.  Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[7]  Alexander Dobrovic,et al.  Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations , 2015, Scientific Reports.

[8]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[9]  B. Dréno,et al.  Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. , 2014, Oncology reports.

[10]  K. Pantel,et al.  Circulating tumor cells and circulating tumor DNA. , 2012, Annual review of medicine.

[11]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[12]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[13]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[14]  M. Denis,et al.  Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation. , 2016, Lung cancer.

[15]  R. Zárate,et al.  Quantitative Cell-Free Circulating BRAF Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors , 2014 .

[16]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[17]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[18]  M. Fleischhacker,et al.  Circulating nucleic acids (CNAs) and cancer--a survey. , 2007, Biochimica et biophysica acta.